Abstract 405P
Background
DFP-14323(INN: Ubenimex) is protease inhibitor of aminopeptidase N (also called CD13), originated from Streptomyces olivoreticuli have been used for maintenance therapy of AML in Japan. Aminopeptidase is well known as one of prognostic factors for several cancer patients, including non-small-cell lung cancer (NSCLC). Otherwise, afatinib is one of the standard treatments in non-small-cell lung cancer (NSCLC) patients with EGFR mutation, but the toxicities often require dose adjustment. Recently, it is suggested that reducing afatinib doses can decrease treatment-related adverse events without affecting efficacy. We aimed to examine efficacy of DFP-14323 with low-dose afatinib by conducting phase II study in patients with metastatic NSCLC harboring EGFR mutation.
Methods
This study was a multi-center, single-arm, open-label phase II trial. Stage III/IV and treatment-naïve patients with common EGFR mutation-positive(L858R or 19del) NSCLC were treated with afatinib at a starting dose of 20 mg/day and DFP-14323 at a fixed dose of 10mg/day until disease progression or intolerable toxicity. Primary endpoint is disease control rate (DCR) defined by sum of CR, PR and SD (RECIST1.1) and secondary endpoints include progression-free survival, overall response rate and safety. A sample size of 26 patients was estimated based on α error of 0.05 (two sided), β error of 0.20, expected DCR 90% and threshold DCR 70% used the Simon’s two stage design.
Results
From July 2018 to March 2020, 26 patients were enrolled. Median age was 72 years (range, 53-82). Twenty-one patients (81%) were female, and 16 (62%) were never-smokers. Mutation subtypes were half Del-19 and half L858R. As of the data cut-off of June 2020, DCR was 100% (26/26) with 17 confirmed PRs. Grade 3 adverse events were observed in 5 (19.2%,1 diarrhea, 1 stomatitis, 2 paronychia, and 1 dermatitis), and all of these events were related with afatinib. No grade 4 or 5 adverse events were observed.
Conclusions
Combination of DFP-14323 and low-dose afatinib showed promising efficacy and good tolerability. We are planning a phase III study to evaluate this combination therapy after evaluation of PFS.
Clinical trial identification
UMIN 000033062.
Editorial acknowledgement
Legal entity responsible for the study
Delta-Fly Pharma Inc.
Funding
Delta-Fly Pharma Inc.
Disclosure
H. Yoshioka: Honoraria (self), a clinical trial coordinator: Delta-Fly Pharma Inc.; Honoraria (self), lecturing: Boehringer Ingelheim. M. Mori, T. Yokoyama, K. Hirano: Honoraria (self), lecture: Boehringer Ingelheim. C-L. Huang: Honoraria (self), a clinical advisor: Delta-Fly Pharma Inc. All other authors have declared no conflicts of interest.
Resources from the same session
61P - Clinical implication of BRCA mutation in breast cancer with central nervous system metastasis
Presenter: Jwa Hoon Kim
Session: e-Poster Display Session
62P - IGF axis in breast cancer recurrence and metastasis
Presenter: Hajara Akhter
Session: e-Poster Display Session
63P - Butterfly pea (<italic>Clitoria ternatea</italic> Linn.) flower extract prevents MCF-7 HER2-positive breast cancer cell metastasis in-vitro
Presenter: Azzahra Asysyifa
Session: e-Poster Display Session
64P - Pre-treatment absolute white blood cell profile count as metastatic predictive factors in invasive ductal carcinoma breast cancer
Presenter: Wikania I Gede
Session: e-Poster Display Session
65P - The new mouse anti-nNav1.5 monoclonal antibody
Presenter: Nur Aishah Sharudin
Session: e-Poster Display Session
66P - The TILs near solid structures is a potential prognostic factor of distant metastases in the luminal HER2-negative breast cancer
Presenter: Vladimir Alifanov
Session: e-Poster Display Session
73P - Selinexor in combination with carboplatin and pemetrexed (CP) in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multi-arm phase Ib study
Presenter: Kyaw Thein
Session: e-Poster Display Session
74P - Comprehensive transcriptome analysis of endoplasmic reticulum stress in osteosarcomas
Presenter: Yoshiyuki Suehara
Session: e-Poster Display Session
75P - The evaluation of selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer
Presenter: Leo Yamada
Session: e-Poster Display Session
76P - Targeted tumour photoImmunotherapy against triple-negative breast cancer therapy
Presenter: Vivek Raju
Session: e-Poster Display Session